These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30841862)

  • 21. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
    J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of rituximab treatment for neuromyelitis optica.
    Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
    Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.
    Huang W; Wang L; Zhang B; Zhou L; Zhang T; Quan C
    Mult Scler Relat Disord; 2019 Oct; 35():246-252. PubMed ID: 31425902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
    Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
    Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
    Zhang M; Zhang C; Bai P; Xue H; Wang G
    Acta Neurol Belg; 2017 Sep; 117(3):695-702. PubMed ID: 28608315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab.
    Romero G; Ticchioni M; Cohen M; Rosenthal-Allieri MA; Mondot L; Lebrun Frenay C
    Rev Neurol (Paris); 2016 Mar; 172(3):220-4. PubMed ID: 26915311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
    Giovannelli J; Ciron J; Cohen M; Kim HJ; Kim SH; Stellmann JP; Kleiter I; McCreary M; Greenberg BM; Deschamps R; Audoin B; Maillart E; Papeix C; Collongues N; Bourre B; Laplaud D; Ayrignac X; Durand-Dubief F; Ruet A; Vukusic S; Marignier R; Dauchet L; Zephir H;
    Ann Clin Transl Neurol; 2021 Oct; 8(10):2025-2037. PubMed ID: 34505407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting.
    Xiao H; Zeng W; Li L; Li L; Cui Y; Wang J; Ye J; Yang Q
    Front Neurol; 2020; 11():642. PubMed ID: 32733365
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
    J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
    D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
    Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.
    Zhao D; Ren K; Lu J; Liu Z; Li Z; Wu J; Xu Z; Wu S; Lei T; Ma C; Zhao S; Bai M; Li H; Guo J
    Front Immunol; 2023; 14():1148632. PubMed ID: 37614240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.
    Magdalena C; Clarissa A; Sutandi N
    Innov Clin Neurosci; 2022; 19(4-6):51-64. PubMed ID: 35958974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
    Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
    Front Neurol; 2022; 13():891064. PubMed ID: 35599732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis.
    Bai P; Zhang M; Yuan J; Zhu R; Li N
    Mult Scler Relat Disord; 2021 Aug; 53():103044. PubMed ID: 34091176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
    Ciron J; Audoin B; Bourre B; Brassat D; Durand-Dubief F; Laplaud D; Maillart E; Papeix C; Vukusic S; Zephir H; Marignier R; Collongues N;
    Rev Neurol (Paris); 2018 Apr; 174(4):255-264. PubMed ID: 29606320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.